Takeda Pharmaceutical Company Limited TAK · SEC Filings

website

47K

Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to th...

Price21.09

Market Cap66.58 B

Float3.12 B

CountryJP

SectorHealthcare

ExchangeNYSE

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

6-K

Takeda Pharmaceutical Reports Financial Results for the Six-Month Period Ended September 30, 2026

Oct 29, 2026

6-K

Takeda Financial Appendix and FY2026 H1 Reported Results

Oct 29, 2026

6-K

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis

Sep 14, 2026

6-K

Takeda Receives U.S. FDA Approval for MIMRYLO™ (rusfertide) to Treat Polycythemia Vera

Aug 28, 2026

6-K

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton) for Narcolepsy Type 1

Aug 5, 2026

6-K

Takeda Pharmaceutical FY2026 Q1 Financial Results and Non-IFRS Definitions

Jul 30, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Jun 26, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jun 26, 2025

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Jun 28, 2024

424B5

PENDING OFFERING | Bank: J.P. Morgan, Morgan Stanley, BofA Securities

Jun 27, 2024

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Jun 30, 2020

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Jun 30, 2020

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

N-PX

Form N-PX - Annual Report of proxy voting record of management investment companies

Aug 20, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT